Are you tempted by the 20% fall in the Vodafone share price? Here’s what you need to know

Vodafone Group plc (LON: VOD) could offer a wide margin of safety and improving growth prospects.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The performance of Vodafone (LSE: VOD) over the last year has been relatively disappointing. The telecoms company’s shares have fallen by 20% during the period, with investors becoming increasingly concerned about its growth prospects and financial standing.

Looking ahead, though, the company is expected to produce double-digit earnings growth in the next financial year. Therefore, it could be worth buying for the long term alongside another growth share which reported positive results on Wednesday.

Improving outlook

The interim results released by healthcare-focused advisory group, Cello Health (LSE: CLL), on Wednesday showed that the company continues to make encouraging progress with its strategy. Headline profit before tax increased by 9.3% to £5.1m versus the first half of the previous year, with the company continuing to deliver on its growth strategy.

During the period, the company was able to increase the profile of its Cello Health brand. It is in the process of building its early stage asset development advisory platform for biotech clients, while also growing its core later stage and post-launch franchise with pharmaceutical clients. Its revenue visibility continues to be underpinned by the depth and breadth of client relationships which it holds, while a focus on increasing the size of the global service platform could improve its long-term financial outlook.

With the company expected to report earnings growth of 9% in the current year, followed by further growth of 7% next year, it appears to have a bright future. Although its price-to-earnings (P/E) ratio of 17 may not be low compared to other small-cap shares, its risk/reward ratio seems to be attractive.

Growth potential

While the Vodafone share price may have fallen in recent months, the company appears to offer an improving outlook. It is expected to post a rise in earnings of 15% in the next financial year. With its shares trading on a price-to-earnings growth (PEG) ratio of 1.2, it seems to offer excellent value for money compared to many of its FTSE 100 peers.

The company’s decision to form partnerships in India and Australia with existing operators could provide it with additional growth catalysts. They could create dominant companies in their respective markets, which could lead to enhanced customer service, economies of scale and higher profitability over the long run. And with the company having a diverse range of operations across the globe, it could benefit from the resilient world GDP growth outlook over the next few years.

Certainly, Vodafone is an unpopular share at the moment. It has a dividend yield of around 8%, and has underperformed many of its FTSE 100 peers in recent months. This situation may take time to change. But with a new CEO having the potential to deliver the company’s growth strategy and it offering a wide margin of safety, now could be the right time to buy it. From a value investing perspective, its long-term investment appeal seems to be high.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Vodafone. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

Surprise! This monopoly stock has taken over my Stocks and Shares ISA (again)

Our writer has a (nice) dilemma in his Stocks and Shares ISA portfolio after one incredible growth stock rocketed higher…

Read more »

Investing Articles

10.5% yield – but could the abrdn share price get even cheaper?

Christopher Ruane sees some things to like about the current abrdn share price. But will that be enough to overcome…

Read more »

Investing Articles

£9,000 to invest? These 3 high-yield shares could deliver a £657 annual passive income

The high yields on these dividend shares sail sit well above the FTSE 100 average of 3.6%. Here's why I…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

I’ve got £2k and I’m on the hunt for cheap shares to buy in December

Harvey Jones finally has some cash in his trading account and is hunting for cheap shares to buy next month.…

Read more »

Investing Articles

Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst?

Harvey Jones bought GSK shares hoping to bag a solid second income stream while nailing down steady share price growth…

Read more »

Investing Articles

Here’s how the Legal & General dividend yield could ultimately hit 15%!

The Legal & General dividend yield is already among the best of any FTSE 100 share. Christopher Ruane explores some…

Read more »

Investing Articles

Is December a good time for me to buy UK shares?

This writer is weighing up which shares to buy for his portfolio next month, and one household name from the…

Read more »

Investing Articles

Is it time to dump my Lloyds shares and never look back?

Harvey Jones was chuffed with his Lloyds shares but recent events have made him rethink his entire decision to go…

Read more »